Shots:
- The P-III EXPLORER-HCM study involves assessing Mavacamten vs PBO in 251 patients in a ratio (1:1) with symptomatic oHCM (LVOT gradient ≥50 mmHg and NYHA Class II-III) for 30wks, followed by an 8-week washout
- Results: @30wks. change in KCCQ OSS in greater than PBO arm; KCCQ OSS ≥20 points (36% vs 15%); a greater proportion of patients in the placebo arm had no change or deterioration in their health status
- Mavacamten is an investigational, first-in-class cardiac myosin inhibitor, in patients with oHCM. The findings of the new analysis are published in the Lancet
Click here to read full press release/ article | Ref: Businesswire | Image: Fierce Pharma
The post BMS Presents Results of Mavacamten in P-III Study for Obstructive Hypertrophic Cardiomyopathy at ACC 2021 first appeared on PharmaShots.
